2. Academic Validation
  3. Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions

Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions

  • J Antimicrob Chemother. 2025 Feb 3;80(2):372-380. doi: 10.1093/jac/dkae413.
Xenia Kostoulias 1 2 3,  Ying Fu 1 4,  Faye C Morris 1 3,  Crystal Yu 1,  Yue Qu 1 2 3,  Christina C Chang 2,  Luke Blakeway 2,  Cornelia B Landersdorfer 3 5,  Iain J Abbott 2 6,  Lynn Wang 1,  Jessica Wisniewski 2,  Yunsong Yu 4,  Jian Li 1,  Anton Y Peleg 1 2 3
Affiliations

Affiliations

  • 1 Infection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.
  • 2 Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
  • 3 Centre to Impact AMR, Monash University, Melbourne, VIC 3800, Australia.
  • 4 Department of Clinical Laboratory, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  • 5 Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia.
  • 6 Microbiology Unit, The Alfred Hospital, Prahran, Melbourne, VIC 3004, Australia.
PMID: 39657684 DOI: 10.1093/jac/dkae413
Abstract

Background: Pseudomonas aeruginosa biofilms limit the efficacy of currently available Antibacterial therapies and pose significant clinical challenges. Pseudomonal biofilms are complicated further when Other markers of persistence such as mucoid and hypermutable phenotypes are present. There is currently a paucity of data regarding the activity of the newer β-lactam/β-lactamase inhibitor combination ceftolozane/tazobactam against P. aeruginosa biofilms.

Methods: We evaluated the efficacy of ceftolozane/tazobactam against clinical P. aeruginosa isolates, the laboratory isolate PAO1 and its isogenic mutS-deficient hypermutator derivative (PAOMS) grown under static and dynamic biofilm conditions. The clinical isolate collection included strains with mucoid and hypermutable phenotypes.

Results: Ceftolozane/tazobactam exposure led to a bactericidal (≥3 log cfu/cm2) biofilm reduction in 15/18 (83%) clinical isolates grown under static conditions, irrespective of carbapenem susceptibility or mucoid phenotype, with greater activity compared with colistin (P < 0.05). Dynamically grown biofilms were less susceptible to ceftolozane/tazobactam with active biofilm reduction (≥1 log cfu/cm2) observed in 2/3 isolates. Hypermutability did not affect the antibiofilm efficacy of ceftolozane/tazobactam in either static or dynamic conditions when comparing PAO1 and PAOMS. Consistent with the activity of ceftolozane/tazobactam as a potent inhibitor of PBP3, dramatic impacts on P. aeruginosa morphology were observed.

Conclusions: Our data demonstrate that ceftolozane/tazobactam has encouraging properties in the treatment of P. aeruginosa biofilm infections, and its activity is not diminished against mucoid or hypermutable variants at the timepoints examined.

Figures
Products